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a b s t r a c t
Glyoxalase 1 (GlxI) is the key enzyme that converts the highly reactive α-oxo-aldehydes into the
corresponding α-hydroxy acids using L-glutathione as a cofactor. In our preliminary data, GlxI was
identiﬁed as a substrate of transglutaminase 2 (TG2), a ubiquitous enzyme with multiple functions.
According to the catalytic properties of TG2, protein cross-linking, polyamine conjugation, and/or
deamidation are potential post-translational modiﬁcations. In this article, we have demonstrated that
TG2 catalyzes either polyamine conjugation or deamidation to GlxI depending on the presence of
polyamines or not. Deamidation leads to activation of GlxI while polyamine conjugation results in
activation of GlxI as well as stabilization of GlxI against denaturation treatment. In cultured HeLa cells,
methylglyoxal challenge causes increase in intracellular levels of reactive oxygen species (ROS) and
calcium leading to TG2 activation and subsequent transamidation and activation of GlxI. The inhibition of
TG2 signiﬁcantly weakens the cell resistance to the methylglyoxal challenge. Thus, GlxI is a novel
substrate of TG2 and is activated by TG2 in vitro and in cellulo. Exposure to methylglyoxal elicits a
negative feedback loop entailing ROS, calcium, TG2 and GlxI, thus leading to attenuation of the increase
in the methylglyoxal level. The results imply that cancer cells highly express TG2 or GlxI can endure the
oxidative stress derived from higher glycolytic ﬂux and may gain extra growth advantage from the
aerobic glycolysis.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Transglutaminases (EC 2.3.2.13) are encoded by a family of nine
structurally related genes, eight of which encode functional
enzymes [1,2]. Among them, transglutaminase 2 (TG2), also called
tissue type transglutaminase, is expressed ubiquitously in many
different cell types. Transglutaminases, in the presence of high
concentrations of calcium, catalyze the formation of isopeptide
linkages between the γ-carboxamide group of the glutamine
residue and the ε-amino group of the lysine residue resulting in
the formation of soluble protein dimer or stable, insoluble macro-
molecular complexes. In addition, low-molecular-mass amines
such as polyamines, can replace lysine residues in the transami-
dating reactions resulting in the formation of N-mono(γ-glutamyl)
polyamines [3,4]. The transglutaminase-catalyzed polyamine con-
jugation possibly alters structure and function of the substrates
since polyamines are polycationic in structure in contrast to the
uncharged property of glutamine side chain. Furthermore, several
noncanonical activities associated with TG2 have been reported
such as deamidation of glutamine residues [5,6], GTP-binding and
hydrolysis [7,8], protein disulﬁde isomerase [9], protein kinase
[10,11] and binding proteins for signaling molecules [12–15].
Methylglyoxal, a highly reactive dicarbonyl compound toward
the amino groups of proteins and nucleic acids, is formed sponta-
neously from glyceraldehyde-3-phosphate and dihydroxyacetone
phosphate generated in the glycolytic pathway [16]. It is estimated
that up to 0.1–2% of arginine residues of cellular proteins and 1 in
105 nucleobases of cellular DNA is modiﬁed by methylglyoxal [17].
Glyoxalase 1 (EC 4.4.1.5; GlxI), a dimeric Zn (II) metalloenzyme
of molecular mass 42 kDa, acts on the hemithioacetal formed
spontaneously from methylglyoxal and glutathione to produce
S-D-lactoylglutathione. Glyoxalase 2 subsequently converts S-D-
lactoylglutathione to D-lactate returning glutathione consumed
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in the reaction catalyzed by GlxI [18,19]. Excessive accumulation of
methylgloxal may induce modiﬁcations of mitochondrial proteins
leading to dysfunction of the mitochondria [20] and increases in
the production of reactive oxygen species (ROS) [21,22]. Further-
more, GlxI overexpression attenuates hyperglycemia-induced
accumulation of methylglyoxal-modiﬁed mitochondrial proteins
and synthesis of ROS and thus enhances the lifespan in Caenor-
habditis elegans [23]. In contrast, inhibition of GlxI reduces mean
and maximum life span of the worms. Similarly, overexpression of
GlxI reduces hyperglycemia-induced levels of advanced glycation
end products and oxidative stress in diabetic rats [24]. Since
accumulation of methylglyoxal leads to increases in ROS [21,22]
and increases in intracellular ROS activate TG2 [25,26], we wish to
investigate whether treatment of cultured cells with methyl-
glyoxal induces activation of TG2 or not. In addition, we wish to
study whether GlxI is regulated by TG2. Our data indicate that TG2
acts on GlxI leading to polyamine–conjugation or deamidation
modiﬁcation depending on the presence of polyamines; deamida-
tion leading to activation and polyamine–conjugation to activation
and stabilization of GlxI. Moreover, activity of TG2 and GlxI
increase in HeLa cells in response to challenged methylglyoxal
and the increase in GlxI activity requires the transamidating
activity of TG2. We propose that exposure of cells to methylglyoxal
elicits a negative feedback loop entailing ROS, calcium, TG2 and
GlxI leading to decrease in the levels of methylglyoxal.
Materials and methods
Afﬁnity puriﬁcation of TG2 substrates
HeLa cells were lysed with 20 mM Tris–HCl, pH 8.0, containing
2 mM CaCl2, 0.1 mM dithiothreitol, 2% Triton X-100 and 1 mM
biotinamidopentylamine (bPA, EZ-Links Pentylamine-Biotin,
Pierce), and the lysate was incubated at 25 1C for 30 min. After
repeated protein precipitation with 80% ammonium sulfate at 4 1C,
the protein pellets were dissolved in TE buffer (20 mM Tris–HCl,
pH 8.0, 5 mM EDTA). The protein samples were then applied to a
streptavidin–agarose (Fluka) column equilibrated with TE buffer.
After washing with 10 bed volumes of TE buffer and 10 bed
volumes of 0.1% SDS in TE buffer, bound proteins were obtained by
boiling in the SDS sample buffer for 5 min.
Constructing plasmids
The ﬁrst-stranded cDNA library was prepared using mRNA
isolated from HeLa cells. Target DNA was ampliﬁed from 50 ng of
cDNA by the Advantage 2 PCR kit (Promega) with the 50 primer
hGlxIF, 50–GTC GAC ATG GCA GAA CCG CA-30, and the 30 primer
hGlxIR, 50–GCG GCC GCC ATT AAG GTT GCC-30, each with endo-
nuclease recognition sites (underlined) for SalI and NotI, respec-
tively. The DNA product was restriction-digested and then ligated
with pET21b expression vector (Novagen) and transformed into
Escherichia coli BL21. With the same procedures, the 50 primer
hGlxIF, 50–AGG CTT ATG GCA GAA CCG CA-30, and the 30 primer
hGlxIR, 50–GAA TTC GCC ATT AAG GTT GCC-30, each with the
endonuclease recognition site (underlined) for HindIII and EcoRI,
respectively, were used for constructing the insert into
p3XFLAG-CMVTM-14 expression vector (Sigma-Aldrich) for
expressing FLAG-GlxI in cells. Although, the deduced amino acid
sequence differs from other isolated sequences with glutamic acid
residue replacing alanine at position 111, the kinetic properties of
recombinant human glyoxalase I (rhGlxI) were indistinguishable
from those of native enzyme [27]. In addition, our rhGlxI has extra
21 amino acid residues to the N-terminus; MASMTGGQQMGKG-
SEFELKKM- due to cloning artifacts.
Preparation and puriﬁcation of anti-spermine antibody
The conjugation of spermine onto bovine serum albumin (BSA)
was carried out by electrolytic reduction and followed by Schiff
base reaction [28]. Ten milligrams of BSA was electrolyzed in 5 ml
of 1% acetic acid containing 0.1 M NaCl at 100 V for 4 h, and the
solution were then adjusted to pH 7.0–8.0 by NaOH prior to
reaction with spermine. The reduced BSA solution was added by
5 ml of 0.1 M spermine and allowed to incubate at 25 1C for 30 min
for Schiff reaction. The spermineconjugated BSA was separated by
preparative SDS-PAGE and the gel band was sliced for preparing
antigens. Anti-spermine antibody was obtained from guinea pig by
subcutaneous injection of spermineconjugated BSA with adjuvant.
The harvested serum was further puriﬁed with spermineconju-
gated agarose. Two milliliter of NHS-activated agarose (Thermo
scientiﬁc) was incubated with 2 ml of 0.5 M spermine in PBS for
3 h and quenched by incubation with 4 ml of 1 M Tris–HCl, pH 8.0.
The IgGs were pulled down by Hitrap Protein A HP column
(GE Healthcare Life Science) in PBS and then eluted by 0.1 M
glycine-HCl, pH 2.8. The eluted IgGs were reconstituted in PBS and
subsequently puriﬁed by spermineconjugated agarose. The afﬁnity
bound IgG by spermineconjugated agarose was eluted by 0.1 M
glycine-HCl, pH 2.8 and reconstituted in PBS as anti-spermine
antibody.
In vitro transamidation
Reaction was carried out by adding TG2 (Sigma-Aldrich), to a
ﬁnal concentration of 50 mU/ml, to a substrate mixture in the TG2
reaction buffer (20 mM Tris–HCl, pH 8.0, 0.15 M NaCl, 0.1 mM DTE,
and 5 mM CaCl2) in the presence of 1 μg/μl bPA at 25 1C for 30 min
incubation. For inhibition of in vitro transamidation, inhibitors
such as EGTA, cysteamine (Fluka), cystamine (Fluka), or mono-
dansylcadeverine (Fluka), each 10 mM at a ﬁnal concentration, was
included in the reaction. Biotin-tagged proteins were resolved by
SDS-PAGE, immunoblotting and streptavidin-peroxidase overlay
assay. For immunoblotting, the protein was recognized by the
speciﬁc antibody, anti-glyoxalase I (FL-184, Santa Gruz biotechnol-
ogy), TG2 (Ab-1, NeoMarkers), or anti-spermine antibody (pre-
pared in house) and magniﬁed by the horseradish peroxidase-
conjugated second antibody (Jackson ImmunoResearch Inc.).
Streptavidin-peroxidase blot overlay
The PVDF membrane was blocked with PBS containing 0.05%
Tween 20 (PBS-T) and 3% skim milk for 1 h and then washed with
PBS-T three times, each for 5 min. For streptavidin-peroxidase blot
overlay, proteins were probed with 1 μg/ml horseradish
peroxidase-conjugated streptavidin (Thermo Scientiﬁc) in PBS-T
containing 3 mg/ml of BSA for 30 min. After washed with PBS-T
three times, each for 5 min, horseradish peroxidase catalyzed
signals were detected with the standard ECL protocol (Millipore).
Detection of TG2-catalyzed deamidation of rhGlxI
Detection of deamidation of GlxI was carried out by two
consecutive reactions with TG2, an initial deamidation and a latter
transamidation in the absence and presence of 1 μg/μl bPA,
respectively. The deamidation reaction was catalyzed by 0 mU to
6 mU of recombinant human TG2 (Zedira, 0.59 U/mg) at 25 1C for
18 h in the TG2 reaction buffer. For the transamidation reaction, to
each sample was then added another 2.5 mU of TG2 and bPA to a
ﬁnal concentration of 1 μg/μl for further incubation at 25 1C for
30min. The samples were then subjected to streptavidin-peroxidase
overlay assay. The extent of deamidationwas revealed by the decreases
in bPA incorporation into rhGlxI. Alternatively, endoproteinase Glu-C
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cleavage was used for detection of the newly generated glutamyl
amino acid residues catalyzed by TG2 [29]. The rhGlxI was
incubated without or with 2 mU TG2 (Zedira) at 25 1C for 18 h in
the TG2 reaction buffer and then added with Glu-C (Sigma-
Aldrich) to 0.1 mU/μl for additional 2 h incubation at 37 1C. The
product was resolved by 10% SDS-PAGE, transferred to a PVDF
membrane, and stained with Amido Black. N-terminal amino acid
sequences (Applied Biosystems Model 477 A) were obtained from
the excised protein bands.
GlxI activity assay
The procedure was modiﬁed from the previous description
[30]. GlxI activity was determined spectrophotometrically in a
reaction buffer containing 8 mM methylglyoxal (Sigma-Aldrich),
1 mM glutathione, 15 mM MgSO4 and 0.2 M imidazole-HCl, pH
7.0 at 25 1C. For 200 μl of reaction, 20 μl of 0.1 μg/μl rhGlxI solution
or cells lysate was added to 180 μl of reaction buffer. The formation
of S-D-lactoylglutathione was monitored by absorbance at 240 nm.
GlxI activity was obtained from each catalytic velocity curve in the
ﬁrst 3 min with 15 s intervals by extrapolating the slope of
absorbance over time.
Cell culture
Cells were obtained originally from American Type Culture
Collection. Cells were cultured in Dulbecco0s Modiﬁed Eagle
Medium (DMEM), high glucose medium containing 10% FBS
within 5% CO2 atmosphere at 37 1C.
In situ transamidation assay
Cells at 80% conﬂuence were primed with fresh serum-free
DMEM medium containing 1 mM bPA for 1–2 h. The cells were
then treated with 0–5 mM methylglyoxal or with 2 mM methyl-
glyoxal in the absence or presence of 1 mM cystamine, 0.1 mM N1-
N11-diethylnorspermine (DENSPM, Tocris), or 0.1 mM monodan-
sylcadaverine (Sigma-Aldrich) for 1–2 h and then harvested by
scraping in a lysis buffer formed by 20 mM Tris–HCl, pH 8.0,
150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% SB 3–12, 1% CHAPS
after PBS wash three times. Each cell lysate was subjected to the
streptavidin-peroxidase blot overlay assay, and the TG2 activity
was evaluated by densitometry analysis of the blots. Endogenous
biotin signals obtained from control cells in the absence of bPA
were subtracted from the calculation. The expression of TG2
activity was normalized to that of the bPA primed and
untreated cells.
Measurement of intracellular methylglyoxal
Methylglyoxal derivatization
The procedures were modiﬁed from the previous description
except that we used 2,3-diaminopyridine (Sigma-Aldrich) instead
of o-phenylenediamine in the derivatization reaction [31]. The
HeLa cells were extracted with 66% methanol in water at a ratio of
600 μl to 1.2106 cells. After centrifugation, 400 μl of supernatant
was vacuum-dried, reconstituted in 20 μl of 20 mM 2,3-diamino-
pyridine (Sigma) in 2.6 mM formic acid and incubated for 24 h at
25 1C. The derivatized samples were ﬁlled up to 100 μl with
ultrapure water for LC-ESI-Q-TOF analysis. Methylglyoxal standard
(1–100 pmol) was used to establish the linear range of reaction.
LC-ESI-MS analysis
The LC-ESI-MS system consisted of an ultra-performance liquid
chromatography (UPLC) system (Ultimate 3000 RSLC, Dionex) and
an electrospray ionization (ESI) source of quadrupole time-of-
ﬂight (TOF) mass spectrometer (maXis HUR-QToF system, Bruker
Daltonics). The autosampler was kept at 4 1C. Separation was
performed with reversed-phase liquid chromatography (RPLC)
on a BEH C18 column (2.1100 mm, Walters). The elution started
from 99% mobile phase A (0.1% formic acid in ultrapure water) and
1% mobile phase B (0.1% formic acid in acetonitrile), raised to 90%
B in 1 min, held at 90% B for 2 min, and then lowered to 1% B in
0.5 min. The column was equilibrated by pumping 1% B for
3.5 min. The ﬂow rate was set at 0.4 ml/min with per injection
volume 10 μl. LC-ESI-MS chromatogram were acquired under the
following conditions: capillary voltage of 4500 V in positive ion
mode, dry temperature at 190 1C, dry gas ﬂow maintained at 8 l/
min, nebulizer gas at 1.4 bar, and acquisition range of m/z 100–
1000. Reaction products of methylglyoxal and 2,3-diaminopyridine
gave rise to signals of at least 6-fold intensity as compared with
that of methylglyoxal and o-phenylenediamine in mass spectro-
metry detection.
Measurement of intracellular ROS and calcium concentration
Cells were treated with 5 μM 20,70-dichloroﬂuorescin diacetate
(DCFH-DA, Sigma-Aldrich) or Fura-2 (Invitrogen) in serum free
DMEM medium for 30 min. The cells were then challenged with
2 mM methylglyoxal in the absence or presence of 1 mM cysta-
mine or 0.1 mM DENSPM in fresh serum free DMEM medium for
2 h. Next, cells were washed with PBS three times and trypsinized
for the ﬂow cytometry analysis with a FACSCaliburﬂow cytometer
(BD Bioscience). The geometric mean of DCF and Fura-2 ﬂuores-
cent intensity was obtained and used for indicating the intracel-
lular ROS levels and [Ca2þ], respectively.
MTT assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide Sigma-Aldrich] in PBS solution (5 mg/ml) was infused
to the culture medium by the ratio 1:10. After 2–5 h, the purple
formazan was dissolved by DMSO and the solution was applied to
measure the absorbance at 560 nm and 670 nm, the latter for
background subtraction. The amount of viable cells was evaluated
by absorbance readout and graphed as a histogram.
Statistics
Statistical comparisons were performed using Student0s
unpaired, two-tailed t test with results expressed as the mean7-
standard deviation (S.D.). A p value ofo0.05 was considered
statistically signiﬁcant.
Cell transfection
Reverse transfection was performed according to the published
procedures [32]. In brief, cells were trypsinized and suspended in
DMEM medium containing 10% FBS. After centrifugation, the cell
pellet was dispersed at the density of 8105 cells in 1 ml of serum
free DMEM medium. DNA or RNA was delivered by using Lipo-
fectamine 2000 reagent (Invitrogen). After 12 h incubation within
5% CO2 at 37 1C, the cells were refreshed with DMEM medium
containing 10% FBS for further 36 h culture.
Short interfering RNA
TGM2, ID: s14087 siRNA(Ambion) was used to knock down TG2
protein expression, GLO1, ID: s5824 or GLO1, ID: s5825 siRNA
(Ambion) was used to knock down GlxI, and negative control #1
siRNA (Ambion) was used for negative control.
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Results
Identiﬁcation of GlxI as a TG2 substrate
From our previous data, GlxI was identiﬁed as one of TG2
substrates from a proteomic survey. For further conﬁrmation, HeLa
cell lysate was incubated with 1 μg/μl biotinamidopentylamine
(bPA) in the presence of 5 mM calcium and 0.1 mM dithiothreitol
for creating TG2-catalyzed transamidation reactions. As a result,
endogenous TG2 would be activated and bPA would be incorpo-
rated into endogenous TG2 substrates. Potential TG2 substrates
were puriﬁed by the streptavidin afﬁnity column chromatography,
biotin-labeled proteins were probed with streptavidin-peroxidase
(Fig. 1A, upper panel) and GlxI was detected by immunoblotting as
a protein band of 24 kD among the biotin-labeled proteins (Fig. 1A,
lower panel). Notice that endogenous biotin-labeled proteins were
puriﬁed from the control cell lysate and those proteins were no
longer puriﬁed from the cell lysate treated with bPA possibly due
to the limited capacity of streptavidin-agarose in the assay. Next,
recombinant human GlxI (rhGlxI) was analyzed by an in vitro
transamidation assay. Recombinant rhGlxI was susceptible to bPA
incorporation catalyzed by TG2 and bPA incorporation was inhib-
ited by TG2 inhibitors; cysteamine, cystamine, EGTA, and mono-
dansylcadaverine (MDC). There was little change in the levels of
monomeric rhGlxI in the presence of TG2 suggesting that TG2 did
not catalyze signiﬁcantly the crosslinking of rhGlxI (Fig. 1B).
Therefore, transamidation with small amine-containing ligands
or deamidation would be the potential modiﬁcations of GlxI
catalyzed by TG2.
Polyamine incorporation and deamidation of Glx1 catalyzed by TG2
Polyamines including putrescine, spermidine and spermine are
the most important amine-containing ligands used by TG2 in the
amine conjugation into TG2 substrates. We then assayed the
incorporation of spermine into GlxI by the in vitro transamidation
assay in the absence or presence of various TG2 inhibitors
(Fig. 2A). Incorporation of spermine into the recombinant GlxI or
proteins in the cell lysate was detected by immunoblotting using
an in-house antiserum against spermine. All known inhibitors of
TG2 potently suppressed the incorporation of spermine into
rhGlxI. Interestingly, rhGlxI seemed to bind spermine strongly
enough to resist SDS-PAGE because the anti-spermine immuno-
blotting recognized the rhGlxI pre-incubated with spermine.
Further, the level of bPA incorporation into rhGlxI was suppressed
by the addition of spermine in the in vitro transamidation
catalyzed by TG2 (Fig. 2B). Along with the decrease in bPA
incorporation, there was an increase in spermine conjugation into
rhGlxI in a dose-dependent manner. Similarly, bPA incorporation
into rhGlxI was also competed by putrescine and spermidine in
the in vitro transamidation, albeit not as potent as spermine
(Fig. 2C). Therefore, all polyamines and bPA can be used by TG2
in the amine incorporation into TG2 substrates and compete with
each other. Besides transamidation, TG2 can cause deamidation,
hydrolysis of the amide group on glutamine side chain, of its
substrates. Besides elaborated analysis using mass spectrometry,
Fig. 1. Conﬁrmation of glyoxalase 1 (GlxI) as a transglutaminase 2 (TG2) substrate.
(A) HeLa cell lysate was subjected to the in vitro transamidation reaction with
endogenous TG2 and substrates in the presence of 1 μg/μl bPA. The bPA labeled
proteins were pulled down using streptavidin-agarose and applied to the biotin
overlay assay (upper panel) and immunoblotting (lower panel). (B) Puriﬁed rhGlxI
was subjected to the in vitro transamidation reaction and applied to the biotin
overlay assay (upper panel) and immunoblotting (lower panel). Lane 1: TG2 only;
lane 2: bPA only; lane 3–7: TG2, bPA and various reagents. CT: control, CTE:
cysteamine, CTA: cystamine, MDC: monodansylcadaverine.
Fig. 2. Polyamination and deamidation of GlxI catalyzed by TG2. (A) Spermine
(SPM) was applied to the in vitro transamidation reaction, in the presence or
absence of TG2 inhibitors, for determination of GlxI polyamination. The products
were analyzed by immunoblotting with an antiserum against spermine. Lane 1:
TG2 only; lane 2: spermine only; lane 3–7: TG2, spermine and various reagents.
(B) Spermine competed with bPA for incorporation into rhGlxI catalyzed by TG2.
(C) Polyamines competed with bPA for incorporation into rhGlxI catalyzed by TG2.
(D) Deamidation of rhGlxI catalyzed by TG2 in the absence of primary amine. In the
absence of primary amine, rhGlxI was incubated with activated TG2 and the level of
deamidation was evaluated by the decrease in incorporation of bPA after further
catalysis of TG2 in the presence of bPA. (E) Deamidation of rhGlxI catalyzed by TG2
in the absence of primary amines. The newly generated glutamic acid residues
catalyzed by TG2 generated new Glu-C cleavage sites. TG2: transglutaminase 2,
CTE: cysteamine, CTA: cystamine, MDC: monodansylcadaverine, PU: putrescine,
SPD: spermidine.
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Gln deamidation can be examined by differential cleavage by Glu-C
protease (also called V8 protease) speciﬁc for Glu residues [29].
However, deamidation also occurs during sample preparation
steps in mass spectrometry prior to the trypsin digestion [33]. To
investigate the deamidation of rhGlxI, the in vitro transamidation
assay was modiﬁed as follows. By pretreating rhGlxI with the
activated TG2 in the absence of primary amines, the amide group
of some glutaminyl residues of rhGlxI would be hydrolyzed by TG2
resulting in conversion to glutamyl residues, which would then be
resistant to further transamidation with the addition of primary
amines. Indeed, pretreatment of rhGlxI with the activated TG2
signiﬁcantly decreased the extent of bPA incorporation at the TG2
doses of 3–6 mU (Fig. 2D). Alternatively, the TG2-treated rhGlxI
either denatured in SDS (right panel) or not (left panel) was
subjected to proteolysis by the endoproteinase Glu-C which is
speciﬁc for glutamate and aspartate residues, but not for gluta-
mine residues. As a result, extra peptide bands were resolved by
SDS-PAGE from which two amino-termini were determined as the
following sequence C-terminal to Gln9 (designated as M10 in the
left panel) and to Gln54 (designated as T55 in the right panel)
(Fig. 2E). The results suggest that TG2 tends to catalyze amine
incorporation into GlxI or deamidation, depending on the pre-
sence or absence of primary amines, instead of protein cross-
linking of GlxI.
Polyamine binding, conjugation and deamidation modulating
GlxI activity and stability
We next examined whether polyamine binding, conjugation
and deamidation of GlxI altered the protein stability or affected
enzyme activity. After treatment with one polyamine or one
polyamine in combination with TG2 for 30 min, the treated rhGlxI
was immediately assayed for its enzyme activity or assayed after
exposure to 25 mM sodium hydroxide treatment for 30 min.
Because a small portion of the enzyme solution was used in the
ﬁnal assay, sodium hydroxide did not change the pH value of the
ﬁnal assay solution. Without TG2 catalyzed reaction, the rhGlxI
activity slightly increased in the presence of putrescine and
spermine. After preincubation with any one of the polyamines,
rhGlxI became resistant to the sodium hydroxide treatment
(Fig. 3A). In contrast, control rhGlxI was prone to denaturation
upon the alkaline treatment rendering it less active later in the
assay. After TG2 catalysis, the activity of rhGlxI either polyamine
conjugated or deamidated increased by more than 80% as com-
pared to that of untreated rhGlxI (Fig. 3B, left panel). No signiﬁcant
difference between polyamine-conjugated and deamidated rhGlxI
in the enzyme activities was found. Polyamine-conjugated rhGlxI
appeared to be resistant to the sodium hydroxide treatment with
only a slight decrease in enzyme activity (Fig. 3B, right panel).
Unexpectedly, deamidated rhGlxI lost its activity to a similar
extent as compared to that of untreated rhGlxI after the sodium
hydroxide treatment. Although noncovalent binding of spermidine
did not stimulate rhGlxI, the enzyme activity of rhGlxI increased in
the presence of spermidine and TG2 reaching to about 2 folds of
that of untreated rhGlxI (Fig. 3C). Overall, the results indicate that
GlxI activity is upregulated by TG2-catalyzed polyamine conjuga-
tion and deamidation. In addition, TG2-catalyzed polyamine con-
jugation causes conformational change of TG2 rendering it more
resistant to alkaline denaturation.
Increases in the levels of ROS and calcium concentration in HeLa
cells in response to methylglyoxal treatment
We next determined intracellular [Ca2þ] in HeLa cells following
methylglyoxal treatment since calcium is required for the activa-
tion of TG2. As a result, intracellular [Ca2þ] signiﬁcantly increased
in methylglyoxal-treated HeLa cells. DENSPM was used to deplete
intracellular polyamines by activating spermidine/spermine acetyl
transferase (SSAT) which would promote the catabolism of endo-
genous spermidine and spermine. The presence of cystamine or
DENSPM did not affect the rise in intracellular calcium induced by
methylglyoxal, but slightly decrease the basal levels of calcium in
HeLa cells (Fig. 4A). Intracellular ROS level in all methylglyoxal-
treated HeLa cells was higher than that in the control cells.
Treatment of both methylglyoxal and cystamine even induced
more ROS in HeLa cells. On the other hand, treatment of cystamine
or DENAPM alone decreased the level of ROS in HeLa cells slightly
(Fig. 4B). The results indicate that following methylglyoxal treat-
ment, levels of intracellular ROS and [Ca2þ] are elevated.
Methylglyoxal treatment activating endogenous TG2 in HeLa cells
Since methylglyoxal is capable of inducing the increase of
intracellular [Ca2þ], TG2 may be activated when cells are challenged
Fig. 3. Modulation of GlxI activity by polyamine binding and TG2-catalyzed modiﬁcations. (A) Effects of polyamines binding on GlxI activity and stability. GlxI was incubated
with one of the polyamines; putrescine (PU), spermidine or spermine, or with an equal volume of TG2 reaction buffer (CT). Two sets of such samples were prepared and one
of themwas then mixed with 25 mM NaOH solution (NaOH) and another with an equal volume of TG2 reaction buffer. After 30 min incubation, 20 μl of the sample was taken
into 180 μl of the assay solution for GlxI activity. The activities of all treated samples were compared with that of CT in the reaction buffer. (B) Effects of TG2 catalyzed
modiﬁcations on GlxI activity and stability. The duplicate samples in Fig. 4A were incubated in the presence of 150 mU/ml TG2. Two sets of such samples were prepared and
one of them was then mixed with 25 mM NaOH solution (NaOH) and another with an equal volume of TG2 reaction buffer. The activities of all treated samples were
compared with that of CT sample in TG2 reaction buffer. (C) Effects of TG2-catalyzed spermidine incorporation on the activity of GlxI. The activity of GlxI was measured after
GlxI was treated with TG2 in the presence of spermidine as compared with that of buffer-treated control. Results were presented as mean of three independent experiments
plus standard error. Results signiﬁcantly different from control at po0.05 are indicated by n.
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by exposure to methylglyoxal. To conﬁrm this notion, in situ
transamidation assay was performed by incubating the cells
with 1 mM bPA in the media. As shown by the extent of bPA
incorporation into the endogenous protein substrates, the endo-
genous TG2 activity was evaluated after methylglyoxal treatment
for 1 h and 2 h. The results showed that endogenous TG2 was
activated as revealed by the incorporation of bPA into cellular
proteins after methylglyoxal treatment. The activity TG2 was
increased up to 2 folds after 2 mM methylglyoxal treatment for
2 h as compared to that of the untreated cells. In addition, further
activation of TG2 was observed at 3, 4, and 5 mM methylglyoxal
for either 1 h or 2 h treatment, with activity increasing up to 4 to
12 folds (Fig. 5A). Then, HeLa cells were treated with 2 mM
methylglyoxal in the presence TG2 inhibitors. The TG2 activity
induced by methylglyoxal treatment was reduced by at least 50%
and 85% with cystamine or by 18% and 60% with MDC as compared
to the methylglyoxal treated cells at 1 h and at 2 h, respectively
(Fig. 5B). In the presence of DENSPM, the TG2 activity remained
elevated at about 2.5 folds as compared to the untreated cells at
1 h and 2 h. The increases in TG2 activity did not result from the
increases in TG2 protein levels (Fig. 5A). In addition, the protein
level of GlxI did not change signiﬁcantly following methylglyoxal
treatment. The data indicate that cystamine and MDC work well in
HeLa cells as TG2 inhibitor but not DENSPM probably because bPA
is used in the assay as the amine donor. Depletion of endogenous
spermidine and spermine would favor the use of bPA as the amine
donor in the amine incorporation reaction. The data indicate that
HeLa cells respond to the methylglyoxal treatment with TG2
activated in a dose-dependent manner.
Transamidation and activation of GlxI in HeLa cells treated
with methylglyoxal
To ﬁnd out whether transamidation of GlxI occurs in HeLa cells,
Flag-rhGlxI was overexpressed in HeLa cells and analyzed for
transamidation by in situ bPA incorporation. Both Flag-rhGlxI
and endogenous GlxI were resolved and appeared to be transami-
dated in methylglyoxal-treated HeLa cells (Fig. 6A) since they were
both tagged with biotin. In addition, the dimer of Flag-rhGlxI and
GlxI was formed in HeLa cells as indicated by the presence of GlxI
in the anti-Flag immunoprecipitates. S-D-lactoylglutathione is the
product of methylglyoxal and glutathione catalyzed by GlxI. The
cell lysate from methylglyoxal-treated cells was used to evaluate
the enzyme activity of GlxI by measuring the turnover of methyl-
glyoxal into the nontoxic S-D-lactoylglutathione in the assay. With
various concentrations of methylglyoxal treatment, GlxI enzyme
activity reached 150% compared to the untreated cells with the
increase of methylglyoxal concentration from 1 to 5 mM (Fig. 6B).
When cells were treated with cystamine and methylglyoxal
together, the turnover rate of S-D-lactolyglutathione dropped at
least by 50% as compared to that treated with methylglyoxal alone.
However, DENSPM only slightly suppressed the methylglyoxal-
induced increases in GlxI activity (Fig. 6C). The data indicate that
Fig. 4. Methylglyoxal treatment caused the increases in intracellular [Ca2þ] and ROS. HeLa cells were incubated in media containing 2 mM methylglyoxal in the absence or
presence of 1 mM cystamine or 0.1 mM DENSPM for 2 h. (A) Intracellular calcium level was determined with Fura-2 by ﬂow cytometry. (B) Intracellular ROS was determined
with DCFH-DA ﬂuorescence by ﬂow cytometry. Results represent an average of three independent experimentsþS.E. Results signiﬁcantly different from control at po0.05
are indicated by n.
Fig. 5. Increases in TG2 activity following methylglyoxal treatment in HeLa cells. HeLa cells were incubated in media containing 1 mM bPA and (A) various concentrations of
methylglyoxal or (B) 2 mM methylglyoxal in the presence of 1 mM cystamine, 0.1 mM DENSPM, or 0.1 mM MDC, and then the cell lysate was subjected to the biotin
overlay assay.
D.-Y. Lee, G.-D. Chang / Redox Biology 2 (2014) 196–205 201
methylglyoxal treatment causes transamidation of GlxI catalyzed
by TG2 resulting in activation of GlxI.
The roles of TG2 and polyamines in HeLa cells in response
to oxidative stress
Suppression of TG2 activity leads to decreases in the turnover
of intracellular methylglyoxal which may result in ROS accumula-
tion. Therefore, we wish to learn whether TG2 activation is
required for HeLa cells to resist oxidative damage induced by
methylglyoxal treatment. HeLa cells were treated with methyl-
glyoxal accompanying TG2 inhibition or polyamine depletion and
then the cell viability was evaluated by the MTT assay. HeLa cells
were treated with methylglyoxal at various concentrations for 24 h
in DMEM medium containing 10% FBS, and the cell death occurred
in a biphasic manner as a function of methylglyoxal concentration.
Methylglyoxal treatment caused maximal cell death at 2 mM, but
viable cells unexpectedly increased under the treatment of
methylglyoxal at 3–5 mM as compared to the treatment of
methylglyoxal at 1–2 mM. According to the results, cystamine
alone did not induce signiﬁcant cell death up to the highest
concentration tested, 1 mM. In combination with cystamine treat-
ment, the same methylgloxal treatment caused more cell death in
a dose-dependent manner, and the unexpected increase in cell
viability at higher concentrations of methylglyoxal treatment was
suppressed by the presence of 0.2, 0.5 and 1 mM cystamine
(Fig. 7A). Thus, HeLa cells treated with cystamine appears more
vulnerable to methylglyoxal treatment, and the biphasic response
to methylglyoxal is suppressed by the cystamine treatment.
However, one should be cautious that cystamine is not a speciﬁc
inhibitor of TG2 [34,35]. The data suggest that treatment of higher
concentrations of methylglyoxal causes activation of TG2 render-
ing cells more resistant to methylglyoxal treatment. Similarly,
HeLa cells treated with DENSPM appeared more vulnerable to
methylglyoxal treatment. However, the biphasic response to
methylglyoxal was only slightly suppressed by DENSPM treatment
(Fig. 7B). In comparison, we also tested the role of TG2 in HeLa
cells in response to staurosporine, an inducer of cell apoptosis.
Cystamine at 1 mM enhanced the effects of staurosporine in
inducing cell death when staurosporine concentration was higher
than 30 μM (Fig. 7C). By contrast, depletion of polyamines in
staurosporine-treated cells caused no extra effect on cell viability
(Fig. 7D). It appears that the role of TG2 in HeLa cell resistance to
staurosporine treatment is less important than to methylglyoxal
treatment. The data indicate that TG2 activation is required for
HeLa cells to resist damage induced by methylglyoxal treatment.
In addition, the effect of GlxI is only partially mediated by
polyamine conjugation.
Expression of TG2 and GlxI are critical for the tolerance against
methylglyoxal assaults
For speciﬁc characterization of TG2 in response to methyl-
glyoxal, siRNA was used to suppress the expression of TG2. TG2-
knockdown cells were exposed to methylglyoxal treatment for
12 h in serum-free DMEM medium. In HeLa cells, 90% of cells
survived after 2 mM methylglyoxal treatment as compared with
that of the control cells, and only 70% of TG2-knockdown cells
survived from 2 mM methylglyoxal treatment. Along with the
knockdown of GlxI, 65% of cells survived after 2 mMmethylglyoxal
treatment as compared with that of the control cells (Fig. 8A).
Moreover, 65% of HepG2 cells survived from 2 mM methylglyoxal
treatment. Along with the knockdown of TG2, 50% of HepG2 cells
survived after 2 mM methylglyoxal treatment as compared with
that of the control cells. Meanwhile, along with the knockdown of
GlxI, the cell viability was only 35% as compared with that of the
control cells after 2 mM methylglyoxal treatment (Fig. 8B). There-
fore, expression of both GlxI and TG2 are beneﬁcial for cell
resistance to the methylglyoxal insults.
Next, we measured the expression levels of TG2 and GlxI in
three different cells and also their tolerance against MG assaults.
The protein expression levels of TG2, GAPDH, and GlxI were
evaluated in a ﬁxed amount of cellular protein. HeLa cells expressed
the highest level of all three enzymes and 3T3 cells expressed the
lowest level of these enzymes. However, COS-1 cells expressed a
similar level of TG2 as compared to that of HeLa cells (Fig. 9A). 3T3
cells appeared to be the most vulnerable, COS-1 next and HeLa
cells the least, to the methylglyoxal treatment (Fig. 9B). At last,
cellular levels of methylglyoxal were determined after 2 h treat-
ment of methylglyoxal in three cells. Under normal culture
conditions, intracellular levels of methylglyoxal were between 14
and 25 μM. Exposure to methylglyoxal resulted in dramatic
increases in intracellular levels of methylglyoxal to 42, 118, and
116 μM in response to 200, 500, and 1000 μM methylglyoxal
exposure, respectively, in 3T3 cells. However, no signiﬁcant change
of intracellular methlglyoxal levels was observed in COS-1 cells,
and methylglyoxal levels in HeLa cells were slightly elevated up to
24, 28, and 35 μM in response to 200, 500, and 1000 μM methyl-
glyoxal exposure, respectively (Fig. 9C). The results indicate that
the expression levels of both GlxI and TG2 are highly correlated
Fig. 6. Methylglyoxal treatment inducing transamidation and activation of GlxI in HeLa cells. (A) HeLa cells expressing Flag-tagged GlxI (Flag-rhGlxI) were incubated in
media containing 1 mM bPA in the presence or absence of 2 mM methylglyoxal for 2 h. Flag-rhGlxI was immunoprecipitated with anti-Flag-agarose and analyzed by the
biotin overlay assay. HeLa cells were incubated with (B) various concentrations of methylglyoxal or (C) 2 mM methylglyoxal in the presence of 1 mM cystamine or 0.1 mM
DENSPM for 2 h, and then GlxI activity in the lysate was monitored by measuring the rate of S-D-lactoylgutathione formation. Results represent an average of three
independent experiments þS.E. Results signiﬁcantly different from control at po0.05 are indicated by n.
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with cell resistance to the methylglyoxal insults. Altogether, the
data suggest that GlxI is required for the disposal of excess
methylglyoxal and shortage of TG2 activity signiﬁcantly impairs
the process.
Discussion
In this communication, we have provided evidence indicating
GlxI is a novel substrate of TG2 whose action elicits Gln deamida-
tion or polyamine conjugation to GlxI. Nonenzymatic deamidation
of Asn and Gln residues is a well-known artifact generated by
analytical steps especially under mildly alkaline pH and prolonged
incubations at 37 1C [36]. Deamidation of Asn at neutral pH usually
proceeds through a cyclic imide reaction mechanism [37] whereas
deamidation of Gln is thermodynamically less favorable in forming
a six-member imide intermediate [38]. Besides elaborated analysis
using mass spectrometry, Gln deamidation can be examined by
differential cleavage by Glu-C protease speciﬁc for Glu residues
[29]. Here we have demonstrated a novel method, called TG2
tandem reaction, for detecting Gln deamidation catalyzed by TG2.
In this practice, TG2 substrates are treated with TG2 twice, ﬁrst for
deamidation and then for primary amine incorporation. Decrease
in the levels of primary amine incorporation reveals the occur-
rence of prior Gln deamidation. In this communication, GlxI
deamidation catalyzed by TG2 has been shown by both the Glu-
C differential cleavage and TG2 tandem reaction methods. Our
results suggest that TG2 tends to catalyze amine incorporation into
GlxI or deamidation, depending on the presence or absence of
primary amines, instead of protein cross-linking of GlxI. In addi-
tion, both deamidation and polyamination greatly enhance the
enzyme activity of GlxI and polyamination renders GlxI more
resistant to alkaline denaturation. The identiﬁed modiﬁcation site
Q54 of the recombinant GlxI corresponds to Q33 of the active site
Fig. 7. Resistance of cultured cells to methylglyoxal treatment or staurosporin (STS) under TG2 inhibition or polyamine depletion. HeLa cells were treated with various
concentrations of methylglyoxal (A, B) or STS (C, D) in the presence of varying concentrations of cystamine or DANSPM for 24 h, and the cell viability was evaluated by MTT
assay. Results represent an average of three independent experiments þS.E. Results signiﬁcantly different from control at po0.05 are indicated by n.
Fig. 8. Resistance of cultured cells to methylglyoxal treatment under TG2 or GlxI
gene knockdown. TG2- or GlxI-knocked down (A) HeLa cells or (B) HepG2 cells
were treated with various concentrations of methylglyoxal and the cell viability
was evaluated by MTT assay. Results represent an average of three independent
experiments þS.E. Results signiﬁcantly different from control at po0.05 are
indicated by n.
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formed by Q33, E99, H126, E172 and zinc ion in native enzyme
[39]. Q33E mutant was demonstrated to lose zinc binding ability
[39]. Our data are not consistent with the previous results. We
speculate that Q33 deamidation or transamidation would not be
the only modiﬁcation caused by TG2. Deamidation or transamida-
tion on sites other than Q33 may increase the stability of GlxI
dimer on the facts that transamidation with spermine provides
opportunities of hydrogen bonding, salt bridges and hydrophobic
interaction and glutamic acid side chain provides salt bridges and
hydrogen bonding, rather than directly engage in catalysis.
TG2 up-regulation has been observed in cells under oxidative
stress [25,26,40,41]. However, its roles in cell response to oxidative
stress remain elusive, depending on the cell type and the kind of
stresses encountered [42,43]. It has been demonstrated that the
transamidation activity of TG2 is required for the survival of
cultured cells in response to various stresses [44–46]. However,
only limited transamidated substrates of TG2 have been shown to
underscore the anti-apoptotic function of TG2; crosslinking of
caspase 3 leading to inhibition [47] and crosslinking of cathepsin D
leading to depletion [48]. In this report, we have added one more
TG2 substrate, GlxI, to this short list whose transamidation results
in stabilization and activation of the enzyme in cells in response to
high concentrations of methylglyoxal. In addition, activation of
GlxI renders cells more resistant to methylglyoxal insult.
Among many altered phenotypes, sustained aerobic glycolysis
(also known as the Warburg effect) is notable for providing
important advantages in tumor growth and survival. Aerobic
glycolysis is preferred over oxidative phosphorylation also in
rapidly proliferating cells such as embryonic stem cells and
lymphocytes. In addition to generating ATP, increases in glycolytic
ﬂux also provides precursors used for the synthesis of nucleic
acids, proteins, and lipids [49]. However, maintaining high levels
of glycolytic intermediates may inevitably lead to production and
accumulation of methylglyoxal. It is conceivable that many tumor
cells overexpress GlxI to dispose the hazardous byproduct of
aerobic glycolysis [50]. In fact, GlxI gene is ampliﬁed in many
primary tumors and cancer cell lines [51] and enzymes involved in
cellular redox balance including GlxI are induced by oncogenic
transformation [52]. Interestingly, expression of TG2 is also ele-
vated in many types of cancer cells resulting in increased cell
invasiveness and cell survival [53–55]. In particular, gene ampli-
ﬁcation of GlxI has been observed in high percentage in breast
cancer [51] and overexpression of TG2 in breast cancer is associated
with higher drug resistance and metastatic potential [56–58].
Our results indicate that the expression levels of both GlxI and
TG2 in cells are correlated with cell resistance to the methylglyoxal
insults, GlxI is required for the disposal of excess methyglyoxal and
shortage of TG2 activity signiﬁcantly impairs the process. We
speculate that overexpression of both TG2 and GlxI confers tumor
cells greater advantage in cell survival, drug resistance and
metastasis since transamidation of GlxI stabilizes and activates
the enzyme. Thus, tumor cells overexpressing both TG2 and GlxI
can endure higher glycolytic ﬂux and may beneﬁt from aerobic
glycolysis without accumulation of methylglyoxal.
Summary
In this article, we have described that (1) GlxI is a novel
substrate of TG2 and TG2 catalyzes either polyamine conjugation
or deamidation depending the presence of polyamines, (2) dea-
midation or polyamine conjugation leads to activation of GlxI or
stabilization and activation of GlxI, respectively, (3) methylglyoxal
challenge causes increases in intracellular levels of ROS and
calcium leading to TG2 activation and transamidation and activa-
tion of GlxI in HeLa cells, (4) both TG2 and GlxI are involved in
cells resistance to methylglyoxal challenge. The data suggest that
exposure to methylglyoxal elicits a negative feedback loop entail-
ing ROS, calcium, TG2 and GlxI leading to decrease in the levels of
methylglyoxal.
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